Compare MAX & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAX | OVID |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.7M | 562.5M |
| IPO Year | 2020 | 2017 |
| Metric | MAX | OVID |
|---|---|---|
| Price | $12.28 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $12.70 | $4.60 |
| AVG Volume (30 Days) | 568.2K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.81 | 3.90 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,113,600,000.00 | $7,252,000.00 |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $8.16 | $19.34 |
| P/E Ratio | $14.30 | ★ N/A |
| Revenue Growth | 28.78 | ★ 1181.27 |
| 52 Week Low | $7.09 | $1.12 |
| 52 Week High | $14.70 | $3.11 |
| Indicator | MAX | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 52.44 |
| Support Level | $11.59 | $2.38 |
| Resistance Level | $14.08 | $2.77 |
| Average True Range (ATR) | 0.50 | 0.15 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 0.66 | 40.91 |
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.